Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.03 USD
Change Today +0.02 / 1.98%
Volume 96.1K
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Timothy G. Daly

AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

43$192,395
As of Fiscal Year 2013

Background*

Mr. Timothy G. Daly served as the Chief Accounting Officer, Vice President and Controller at Enzon Pharmaceuticals Inc. from December 19, 2011 to August 9, 2013 and also served as its Principal Financial Officer until August 9, 2013. Mr. Daly has more than 12 years of experience in the biotech and pharmaceutical healthcare industry. Since 2006, he served as a Director of Finance at ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company. During his tenure ...

Read Full Background

Corporate Headquarters*

20 Kingsbridge Road
Piscataway, New Jersey 08854

United States

Phone: 732-980-4500
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BA
Rider University

Other Affiliations*

Annual Compensation*

Salary$158,626
Total Annual Compensation$158,626

Stock Options*

All Other Compensation$248
Exercisable Options5,000
Total Number of Options5,000

Total Compensation*

Total Annual Cash Compensation$192,395
Total Short Term Compensation$158,626
Other Long Term Compensation$248
Total Calculated Compensation$192,395
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZN:US $1.03 USD +0.02

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Judith Greciet Ph.D., PharmacyChief Executive Officer, Director and Member of Corporate Development Committee
Onxeo SA
€276.9K
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
William John Edward Burt DPhilChief Executive Officer and Executive Director
Abzena plc
--
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZON PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.